temsirolimus - Compound Summary (CID 6918289)
Also known as: Torisel, CCI-779, NCGC00167518-01, Temserolimus, S1044_Selleck, 162635-04-3, CHEMBL1201182, Torisel, CCI-779, Temsirolimus, NSC-683864
Molecular Formula: C56H87NO16   Molecular Weight: 1030.28708   InChIKey: CBPNZQVSJQDFBE-FUXHJELOSA-N
Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.   From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Pharmacology
Biomedical Effects and Toxicity
Safety and Handling
Exposure Standards and Regulations
Literature
Patents
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _